Transdermal rotigotine improves sleep fragmentation in parkinson's disease : Results of the multicenter, prospective SLEEP-FRAM study
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau)
Piñol, Gerard (Hospital Universitari Santa Maria (Lleida))
Cardozo, Adriana (Hospital Universitari Santa Maria (Lleida))
Sanz, Pilar (Hospital de Mataró. Consorci Sanitari del Maresme)
Puente, Víctor (Hospital del Mar (Barcelona, Catalunya))
Otermín, Pilar (Hospital General de Granollers)
Legarda, Inés (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Delgado, Tania (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Serrano, Carmen (Hospital de Martorell)
Balaguer, Ernest (Hospital General de Catalunya)
Aguirregomozcorta, María (Hospital de Figueres)
Álvarez, Ramiro (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2015
Abstract:	Sleep disturbances occur frequently in patients with Parkinson's disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8. 9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson's Disease Sleep Scale (PDSS). The newly designed Parkinson's Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70. 2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from 3. 4 ± 0. 9 to 1. 9 ± 1. 4; P < 0. 0001). Rotigotine also significantly improved nocturnal motor symptoms P < 0. 0001, restless legs-like symptoms P < 0. 005, and nocturia P = 0. 004. Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Parkinson's Disease, Vol. 2015 (22 2015) , p. 131508, ISSN 2042-0080

DOI: 10.1155/2015/131508
PMID: 25793143

7 p, 571.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles